地拉罗司中国上市了吗？

(Enrig) Is it listed in China? Deferasirox (Enrega) was the first oral iron chelator approved by the FDA for routine use in 2005 and is now available in more than 80 countries. The oral suspension and dispersible tablets marketed in the United States are approved for the treatment of chronic iron overload due to transfusion in adult and pediatric patients 2 years and older and for the treatment of chronic iron overload in patients 10 years and older with non-transfusion-dependent thalassemia (NTDT) syndrome.

In 2010, Deferasirox (Enrige) was approved for marketing in China for the treatment of chronic iron overload in β-thalassemia patients older than 6 years old due to frequent blood transfusions (monthly dosage of concentrated red blood cells ≥7 mL/kg). For children under 6 years old and iron overload caused by other transfusion-dependent diseases, the safety and effectiveness data of deferasirox (Enrige) in Chinese patients are limited, and it is recommended to use it with caution based on the specific conditions of the patients.

In addition, iron chelators are a new type of iron removal treatment based on directional binding of iron ions in the body, effectively increasing iron excretion, reducing iron content in the body and its pathological deposition in various organs. It is currently the only effective drug for the treatment of iron overload.

The application of iron chelators has greatly reduced the mortality rate and improved the quality of life of patients with long-term blood transfusions, and its clinical application has been receiving widespread attention and attention. The iron chelators currently used in clinical practice mainly include deferoxamine (DFO), deferiprone (DFP), and deferasirox (Enrige).

Deferasirox (Enrige) is currently the only oral iron chelator developed by Novartis. Its indications are: 1. Patients with chronic iron overload transfusion hemosiderinosis secondary to blood transfusion who are 2 years old or older. Chronic iron overload symptoms will occur when serum ferritin continues to be >1000 L. Iron chelation therapy should be started at this time. 2. Iron chelator therapy can also be given to patients undergoing ASCT treatment when iron overload occurs; 3. (Enrig) ​​can be used to treat reversible renal insufficiency caused by Fanconi syndrome.

Recommended related hot articles: /newsDetail/75977.html